Levobupivacaine Altan Pharma (Levobupivacaine)

Levobupivacaine is employed in regional anesthesia and pain control through epidural and peripheral nerve block techniques.

• Regional anesthesia: provides dense sensory and motor block for surgical procedures requiring nerve blockade.
• Epidural analgesia: delivers continuous pain relief during labor, delivery, or postoperative periods.
• Surgical anesthesia: facilitates anesthesia for operations where a rapid onset and prolonged duration are needed.

• Levobupivacaine exerts its effect by reversibly binding to the intracellular portion of voltage‑gated sodium channels in neuronal membranes. This blocks the influx of sodium ions during depolarization, preventing the generation and propagation of nerve impulses. The resulting inhibition of signal transmission produces a reversible loss of sensation and motor function in the targeted area, with a duration longer than that of bupivacaine due to its stereoselective configuration.

Adverse reactions to levobupivacaine may vary in frequency and severity.

Common Side Effects

• Hypotension: decreased blood pressure following epidural administration.
• Bradycardia: slowed heart rate observed during or after dosing.
• Dizziness: transient light‑headedness or vertigo.
• Nausea: mild gastrointestinal upset.
• Metallic taste: transient alteration in taste perception.
• Headache: post‑dural puncture or medication‑related headache.

Serious or Rare Side Effects

• Cardiac arrest: severe cardiotoxicity leading to loss of cardiac function.
• Seizures: central nervous system excitation causing convulsions.
• Respiratory depression: reduced breathing effort requiring support.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Prolonged motor block: extended loss of muscle function beyond expected duration.
• Methemoglobinemia: abnormal hemoglobin causing reduced oxygen delivery.

When using levobupivacaine, clinicians should observe several safety precautions to minimize risks.

• Cardiac monitoring: observe ECG and blood pressure continuously during administration.
• Avoid intravascular injection: aspirate before injection and monitor for signs of systemic toxicity.
• Hepatic impairment: adjust dose or monitor closely in patients with liver dysfunction.
• Elderly patients: use reduced initial doses due to increased sensitivity.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Levobupivacaine may interact with other medicines, affecting its safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine): increase risk of cardiotoxicity.
• Beta‑blockers: may exacerbate bradycardia and hypotension.
• High‑dose general anesthetics (e.g., propofol): additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• Opioids: enhanced respiratory depression when combined.
• NSAIDs: potential increase in bleeding tendency.
• Magnesium sulfate: potentiates neuromuscular blockade.